New drug AVM0703 tested for Life-Threatening ARDS
Disease control
Not yet recruiting
This early-stage study tests a single dose of AVM0703 in 16 adults with severe breathing failure (ARDS) caused by COVID-19 or influenza. The main goal is to check safety and find the right dose. Participants are randomly assigned to get the drug or a placebo, and no one knows who…
Phase: PHASE1 • Sponsor: AVM Biotechnology Inc • Aim: Disease control
Last updated May 15, 2026 12:00 UTC